Changing Paradigm of the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
First Online: 22 July 2010 DOI:
10.1007/s11899-010-0061-y Cite this article as: Ohno, R. Curr Hematol Malig Rep (2010) 5: 213. doi:10.1007/s11899-010-0061-y Abstract
In the pre-imatinib era, the treatment outcome of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph
+ ALL) was dismal. Complete remission was generally achieved only in about 50% to 60% of patients, and allogeneic hematopoietic stem cell transplantation (allo-HSCT), when feasible in younger patients, was virtually the sole curative modality. Imatinib has changed the situation dramatically, however, in combination with conventional chemotherapy or with corticosteroid alone, producing about 95% complete remission and thus increasing the number of patients undergoing allo-HSCT. Currently, the overall survival of patients who have undergone allo-HSCT exceeds 50%, and a considerable proportion of patients for whom allo-HSCT is not feasible are predictably curable. The next question is how to prevent relapse, which is observed not only in more than half of patients for whom allo-HSCT is not feasible but also in a considerable number of patients after allo-HSCT. Thus, improvement of postremission therapy is crucial. Whether intensive chemotherapy with currently available cytotoxic drugs contributes to the prevention of relapse is questionable, because intensive chemotherapy alone in the pre-imatinib era nearly always failed to cure this disease. Promising partners to be combined with imatinib or with a second-generation tyrosine kinase inhibitor (TKI) will be corticosteroids and vincristine. New TKIs such as dasatinib should be incorporated into the early phase of postremission therapy. Recognizing the small number of patients with Ph + ALL, intergroup or international studies are necessary to develop the best postremission therapy. In the near future, it is hoped that Ph + ALL will become one of the leukemias for which allo-HSCT is offered only for relapsed or extremely high-risk patients. Keywords Acute lymphoblastic leukemia Philadelphia chromosome Ph+ ALL BCR-ABL Imatinib Dasatinib Nilotinib Tyrosine kinase inhibitor TKI Prognostic factors References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983–3993.
Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166–178.
Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.
Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:118–122.
Aricò M, Valsecchi MG, Camitta B, et al.: Outcome of treatment in children with Philadelphia chromosome–positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998–1006.
Schrappe M, Aricò M, Harbott J, et al.: Philadelphia chromosome–positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730–2741.
Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357–2366.
Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993 ) [abstract]. Blood 2001, 98:856a.
Tanimoto M, Miyawaki S, Ino T, et al.: Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 1998, 68:421–429.
Ueda T, Miyawaki S, Asou N, et al.: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998, 68:279–289.
Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259–1266.
Kantarjian H, Thomas D, O’Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788–2801.
Thomas DA: Philadelphia chromosome–positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007:435–443.
Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.
Ohno R: Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 2006, 11:176–183.
Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.
Ohno R, Japan Adult Leukemia Study Group: Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Curr Hematol Malig Rep 2006, 1:180–187.
Ohno R: Treatment of adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Curr Oncol Rep 2008, 10:379–387.
Yanada M, Ohno R, Naoe T: Recent advances in the treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia. Int J Hematol 2009, 89:3–13.
Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia. Blood 2004, 104:3507–3512.
Yanada M, Takeuchi J, Sugiura I, et al: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.
Yanada M, Sugiura I, Takeuchi J, et al.: Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome–positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008, 143:503–510.
Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.
Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2006, 108:1469–1477.
de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408–1413.
Ribera JM, Oriol A, González M. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010, 95:87–95.
• Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676–3678.
This is the first report that imatinib plus steroid induced 100% CR in elderly patients with Ph
Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL). Cancer 2007, 109:2068–2076.
Delannoy A, Delabesse E, Lhéritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526–1532.
•• Schultz KR, Bowman WP, Aledo A: Improved early event-free survival with imatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009, 27:5175–5181.
This very informative report on Ph + ALL shows that, after standard induction chemotherapy, long-term imatinib plus intensive chemotherapy resulted in 88% EFS, dramatically better than historical controls, and therapy with imatinib and chemotherapy was in no way inferior to allo-HSCT
Yanada M, Takeuchi J, Sugiura I, et al: Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia treated with imatinib–combined chemotherapy. Haematologica 2008, 93:287–290.
Wassmann B, Pfeifer H, Stadler M, et al.: Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2005, 106:458–463.
Lee S, Kim YJ, Chung NG et al.: The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia. Cancer 2009, 115:561–570.
O’Hare T, Eide CA, Deininger MW: Bcr–Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242–2249.
Branford S, Rudzki Z, Walsh S, et al.: Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276–283.
O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr–Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.
Pfeifer H, Wassmann B, Pavlova A, et al.: Kinase domain mutations of BCR–ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2007, 110:727–734.
Hu Y, Liu Y, Pelletier S, et al.: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1–induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453–461.
Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res 2010, 184:83–102.
Ottmann O, Dombret H, Martinelli G, et al.: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110:2309–2315.
Porkka K, Koskenvesa P, Lundán T, et al.: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood 2008, 112:1005–1012.
Lilly MB, Ottmann OG, Shah NP, et al.: Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010, 85:164–170.
• Ravandi F, Kantarjian HM, Thomas DA, et al.: Phase II study of combination of the HyperCVAD regimen with dasatinib in the front line therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 837.
Dasatinib plus intensive chemotherapy induced a high CR rate in newly diagnosed adult Ph
+ ALL, but the severe adverse events should not be overlooked.
Quintás-Cardama A, Kantarjian H, Ravandi F: Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009, 115:2482–2490.
Quintás-Cardama A, Han X, Kantarjian H, Cortes J: Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009, 114:261–263.
• Foà R, Vitale A, Guarini A, et al.: Front-line treatment of adult Ph + acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 Study [abstract 305]. Blood (ASH Annual Meeting Abstracts) 2008, 112:119a.
This informative abstract reported that dasatinib plus steroid induced 100% CR in newly diagnosed adult Ph
+ ALL without remarkable adverse events.
Ottmann OG, Larson LA, Kantarjian HM: Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) who are resistant or intolerant to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:abstract 2815.
Ohno R, Asou N, Ohnishi K: Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17:1454–1463.
Riva G, Luppi M, Barozzi P, et al.: Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph + acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood 2010, 115:1512–1518.
Kim DH, Kamel-Reid S, Chang H: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009, 94:135–139.
Mustjoki S, Ekblom M, Arstila TP, et al.: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23:1398–1405.
Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly use antileukemic agents. Blood 2001, 97:1999–2007.
Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl–positive cells. Blood 2000, 96:3195–3199.
Hongo T, Okada S, Inoue N, et al.: Two groups of Philadelphia chromosome–positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol 2002, 76(3):251–259.
Ramakers-van Woerden NL, Pieters R, Hoelzer D, et al.: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 2002, 38:379–386.
© Springer Science+Business Media, LLC 2010